Additionally, the dependence of FRA-1 activity on ERK activation suggests that tumors (such as pancreatic cancer) bearing activating mutations with the Ras-Raf-MEK-ERK cascade are likely to exhibit FRA-1 based effects. Here, MAP2K7 is linked to pancreatic neoplasm.